169 related articles for article (PubMed ID: 9829839)
1. Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells.
Shimizu M; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
Cancer Immunol Immunother; 1998 Nov; 47(3):143-8. PubMed ID: 9829839
[TBL] [Abstract][Full Text] [Related]
2. Role of Egr-2 in up-regulation of Fas ligand in normal T cells and aberrant double-negative lpr and gld T cells.
Mittelstadt PR; Ashwell JD
J Biol Chem; 1999 Jan; 274(5):3222-7. PubMed ID: 9915863
[TBL] [Abstract][Full Text] [Related]
3. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
[TBL] [Abstract][Full Text] [Related]
4. Lymphocytes with aberrant expression of Fas or Fas ligand attenuate immune bone marrow failure in a mouse model.
Omokaro SO; Desierto MJ; Eckhaus MA; Ellison FM; Chen J; Young NS
J Immunol; 2009 Mar; 182(6):3414-22. PubMed ID: 19265119
[TBL] [Abstract][Full Text] [Related]
5. Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts.
Djamali A; Odorico JS
Transplantation; 1998 Dec; 66(12):1793-801. PubMed ID: 9884278
[TBL] [Abstract][Full Text] [Related]
6. Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders.
Watanabe D; Suda T; Hashimoto H; Nagata S
EMBO J; 1995 Jan; 14(1):12-8. PubMed ID: 7530197
[TBL] [Abstract][Full Text] [Related]
7. Modification of tumor cells with Fas (CD95) antigen gene and Fas ligand (CD95L) gene transfection by electroporation for immunotherapy of cancer.
Shimizu M; Yoshimoto T; Matsuzawa A; Takeda Y
Mol Biotechnol; 2003 Sep; 25(1):79-87. PubMed ID: 13679638
[TBL] [Abstract][Full Text] [Related]
8. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
[TBL] [Abstract][Full Text] [Related]
9. A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo.
Shimizu M; Yoshimoto T; Nagata S; Matsuzawa A
Biochem Biophys Res Commun; 1996 Nov; 228(2):375-9. PubMed ID: 8920922
[TBL] [Abstract][Full Text] [Related]
10. Renal tubular epithelial cell apoptosis by Fas-FasL-dependent self-injury can augment renal allograft injury.
Du C; Guan Q; Yin Z; Masterson M; Zhong R; Jevnikar AM
Transplant Proc; 2003 Nov; 35(7):2481-2. PubMed ID: 14611992
[TBL] [Abstract][Full Text] [Related]
11. Abnormal IgG galactosylation and arthritis in MRL-Fas(lpr) or MRL-FasL(gld) mice are under the control of the MRL genetic background.
Kuroda Y; Nakata M; Nose M; Kojima N; Mizuochi T
FEBS Lett; 2001 Oct; 507(2):210-4. PubMed ID: 11684100
[TBL] [Abstract][Full Text] [Related]
12. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
13. Significant role of Fas ligand-binding but defective Fas receptor (CD95) in lymph node hyperplasia composed of abnormal double-negative T cells.
Matsuzawa A; Shimizu M; Takeda Y; Nagase H; Sayama K; Kimura M
Immunology; 2002 Aug; 106(4):470-5. PubMed ID: 12153509
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved.
Kim S; Kim KA; Hwang DY; Lee TH; Kayagaki N; Yagita H; Lee MS
J Immunol; 2000 Mar; 164(6):2931-6. PubMed ID: 10706679
[TBL] [Abstract][Full Text] [Related]
15. Cellular interactions in the lpr and gld models of systemic autoimmunity.
Sobel ES
Adv Dent Res; 1996 Apr; 10(1):76-80. PubMed ID: 8934931
[TBL] [Abstract][Full Text] [Related]
16. Tumor-derived Fas ligand induces toxicity in lymphoid organs and plays an important role in successful chemotherapy.
Nagarkatti N
Cancer Immunol Immunother; 2000 Apr; 49(1):46-55. PubMed ID: 10782865
[TBL] [Abstract][Full Text] [Related]
17. Gammadelta T cells promote a Th1 response during coxsackievirus B3 infection in vivo: role of Fas and Fas ligand.
Huber S; Shi C; Budd RC
J Virol; 2002 Jul; 76(13):6487-94. PubMed ID: 12050361
[TBL] [Abstract][Full Text] [Related]
18. Growth of FasL-bearing tumor cells in syngeneic murine host induces apoptosis and toxicity in Fas(+) organs.
Zeytun A; Nagarkatti M; Nagarkatti PS
Blood; 2000 Mar; 95(6):2111-7. PubMed ID: 10706882
[TBL] [Abstract][Full Text] [Related]
19. Amelioration of lymphoid hyperplasia and hypergammaglobulinemia in lupus-prone mice (gld) by Fas-ligand gene transfer.
Hong NM; Masuko-Hongo K; Sasakawa H; Kato T; Shirai T; Okumura K; Nishioka K; Kobata T
J Autoimmun; 1998 Aug; 11(4):301-7. PubMed ID: 9776707
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions.
Davidson WF; Giese T; Fredrickson TN
J Exp Med; 1998 Jun; 187(11):1825-38. PubMed ID: 9607923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
